Marianne Pavel.

If an individual was withdrawn from the study prematurely for reasons other than death or centrally assessed disease progression, further imaging lab tests were required unless the previous test had taken place within the last 4 weeks. Disease progression was assessed centrally regarding to RECIST, version 1.0. Assessment of baseline hepatic tumor volumes, measurement of serum chromogranin A and lanreotide levels, and antibody testing are defined in the Supplementary Appendix. Basic safety assessments included monitoring for adverse occasions, physical evaluation and monitoring of vital symptoms , electrocardiography and ultrasonography of the gallbladder , and clinical laboratory exams . The principal end point was progression-free survival, defined as enough time to disease progression or death within 96 weeks following the first injection of the study drug.The company said it sold $2.27 billion worth of Sovaldi in the one fourth that ended March 31. $2.27 billion! The boffo number beat Wall Street's estimate for the quarter by more than $1 billion . PBS NewsHour: New Hepatitis-C Drug Raises Wish At A Hefty Price A new drug has a 90 to 100 % chance of curing the Hepatitis-C virus, but costs tens of thousands of dollars for a treatment. The announcement by the product manufacturer that it earned a lot more than $2 billion in the year's first one fourth raises the relevant query, who should pay when drugs are highly effective, but extremely expensive? Hari Sreenivasan reviews on the profits, insurance and costs . This content was reprinted from kaiserhealthnews.org with permission from the Henry J.